Aurora Cannabis has acquired two UK businesses — licensed importer and wholesaler Internode Pharma Limited and licensed pharmacy HAP Pharma Limited — for GBP 2.1 million in cash paid at closing, according to the company's announcement dated 19 August 2026.
The purchase was made indirectly through a wholly owned subsidiary, which bought 100% of the shares of both companies. The release states the cash consideration is contingent on the satisfaction of certain post-closing conditions, without specifying what those conditions are. No earn-out, share issuance or debt component was disclosed, and Aurora did not publish revenue, earnings or asset figures for either acquired business.
Both entities are based in Birmingham. Between them they operate a licensed import and distribution facility and a virtual pharmacy — that is, a dispensing operation that fulfils prescriptions remotely rather than over a shop counter. Aurora says the combination gives it ownership of the chain from cultivation through to delivery to the patient, replacing arrangements in which third parties handled the final steps.
Aurora frames the deal around market size rather than current sales. The company describes the United Kingdom as one of Europe's largest medical cannabis markets and cites a population of roughly 70 million people. It does not give a figure for the value of that market, its own current UK revenue, or the number of patients served.
On the financial effect, the release says the transaction is expected to be accretive to adjusted EBITDA in future quarters, attributing that to operational efficiencies and less reliance on outside distributors. Adjusted EBITDA is a non-standard earnings measure that Aurora defines itself and that is not recognised under IFRS accounting rules; the company points readers to its FY27 Q1 management discussion and analysis for the definition. No quantified contribution and no timeframe were provided, so the claim cannot be checked against a number at this stage.
Executive Chairman and Chief Executive Miguel Martin said the acquisition would let Aurora "expand our market share, while also supporting a consistent and reliable supply of high-quality medical cannabis products to UK patients." He also pointed to what he called increasingly prescriptive regulatory standards in the UK as part of the rationale.
Aurora added that it intends to evaluate further UK distribution acquisitions to add capacity, without naming targets, budgets or timing.
What the release does and does not establish
The verifiable content of the announcement is narrow: a completed share purchase, a stated cash price, the licences held by the two targets, and their location. Everything concerning market share gains, supply reliability and earnings contribution is presented as company expectation, and Aurora lists integration risk — specifically "the risk of successful integration of acquired business and operations" — among the factors that could affect the outcome.
For context on scale, GBP 2.1 million is a small outlay for a company listed on both Nasdaq and the Toronto Stock Exchange, and the release contains no information on Aurora's cash position or how the payment was funded. Nor does it disclose whether the acquired businesses were already distributing Aurora product before the deal, which would determine whether the transaction adds revenue or internalises margin that Aurora was previously paying away.
Aurora sells into medical and consumer markets in Canada, Europe, Australia and New Zealand, and holds GMP-certified manufacturing sites in Canada and Germany. GMP, or good manufacturing practice, is the pharmaceutical quality standard required for medical cannabis supply in most European markets, including the UK.
Readers looking for the financial follow-through will need Aurora's next quarterly filing, where any UK distribution revenue and the acquisition accounting would first appear.
Source: PR Newswire
This article is journalism, not investment advice. It is not an offer or solicitation to buy or sell any security. Micro-cap and penny stocks carry a high risk of loss, including illiquidity and dilution. Do your own research.